Search | Clinical Trials Finder

Conditions: Glycogen Storage Disease Type II;Pompe's Disease
Interventions: Avalglucosidase alfa (GZ402666), Alglucosidase alfa (GZ419829); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 3 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 18 more

Conditions: Renal Insufficiency, Chronic, Hyperkalemia
Interventions: Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 42
States / cities: Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Afrezza; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 8 more

Conditions: Malignant Pleural Mesothelioma, Solid Tumors
Interventions: pemetrexed, cisplatin and CBP501, pemetrexed and cisplatin, pemetrexed, cisplatin and CBP501, dose finding; Drug
Lead sponsor: CanBas Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 12
States / cities: Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 9 more

Conditions: Cardiovascular Disease
Interventions: Soy Protein Powder (25g/d), Placebo, Soy Protein Powder (50g/d); Dietary Supplement
Lead sponsor: Penn State University; Other
Eligibility: 35 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Opioid Pain Medication
Interventions: Tranexamic acid, Aminocaproic acid, Recombinant Human Thrombin, Lidocaine Hydrochloride with Epinephrine, Bupivacaine Hydrochloride with Epinephrine; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus
Interventions: Insulin; Drug
Lead sponsor: QDose Limited; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Clostridioides Difficile Infection, Clostridium Difficile Infection, Clostridium Difficile Diarrhea, Clostridia Difficile Colitis
Interventions: Alanyl-glutamine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 105 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Charlottesville, Virginia • Roanoke, Virginia

Conditions: Amyotrophic Lateral Sclerosis ALS
Interventions: Astaxanthin, Protandim, Melatonin, MitoQ; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Gastrointestinal Tolerance
Interventions: Hydrolyzed protein infant formula with oligosaccharides; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 0 Days to 90 Days
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Orange City, Florida • Fayetteville, Georgia + 4 more

Conditions: Hepatitis, Alcoholic
Interventions: IMM 124-E (Hyperimmune Bovine Colostrum), Placebo (High protein milk powder); Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Indianapolis, Indiana • Rochester, Minnesota • Richmond, Virginia

Conditions: Acute Kidney Injury
Interventions: Creatine Monohydrate, Creatine Ethyl Ester; Dietary Supplement
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Embolism, COVID
Interventions: TNKase, Placebo, Enoxaparin; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Gastrointestinal Tolerance
Interventions: Phase 1- Arm 1 Infant Formula, Phase 2- Arm 2 Infant Formula, Phase 2- Arm 3 Infant Formula; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: Up to 30 Days
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 6
States / cities: Tucson, Arizona • St. Petersburg, Florida • Asheboro, North Carolina + 3 more

Conditions: Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Gemcitabine, Nab-paclitaxel, L-glutamine; Drug
Lead sponsor: Jun Gong, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Beverly Hills, California • Los Angeles, California

Conditions: Weight Loss, Gut Microbiome, Anti-Aging
Interventions: P-IF, HH; Behavioral
Lead sponsor: Skidmore College; Other
Eligibility: 25 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Saratoga Springs, New York

Conditions: Diverticulosis, Colonic
Interventions: L-glutamine; Drug
Lead sponsor: Emmaus Medical, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Torrance, California • Ventura, California • San Antonio, Texas

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Capsule + Powder supplementation, stable tracer infusion; Dietary Supplement · Other
Lead sponsor: Texas A&M University; Other
Eligibility: 45 Years to 100 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Diet Habit, Diet Modification, Taste, Altered, Saliva Altered
Interventions: Chocolate Milk, Chocolate milk substitute, Chocolate milk substitute with gelatin; Other
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Arthritis, Rheumatoid
Interventions: Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri

Conditions: Major Depressive Disorder
Interventions: 5-Hydroxytryptophan 100 MG, Creatine monohydrate, placebo matched to 5-HTP, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 25 Years to 40 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Celiac Disease
Interventions: Placebo, TAK-101, Gluten; Drug · Dietary Supplement
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 26
States / cities: Scottsdale, Arizona • Escondido, California • Poway, California + 17 more

Conditions: Chronic Idiopathic Urticaria
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 40
States / cities: Birmingham, Alabama • Huntington Beach, California • Long Beach, California + 37 more

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 28
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 22 more

Search by objective public record fields.

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

Effect of Soy on HDL-C Function, Central Blood Pressure, and Arterial Stiffness

Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler

Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

Infants Fed a Hydrolyzed Infant Formula

Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis

Effect of Creatine on Serum and Urine Creatinine

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

Tolerance of Healthy Infants Fed Infant Formulas

Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women

L-glutamine Treatment in Patients With Diverticulosis

Fish Oil and HMB Supplementation in COPD

Interaction of Salivary Proteins and Polyphenols

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

5-HTP and Creatine for Depression

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]